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Before going into detail the biological effects of vitamin K2, it must be emphasized that vita-
min K2, also known as menaquinones with varying side chain lengths, may in fact associate 
with other genes and modulate their effects substantially.
In fact, vitamin K2 may associate with a protein nuclear factor or intra‐nuclear hormone 
receptor, just like what is known for vitamin A and vitamin D. This protein has many names, 
such as NR1I2, PXR or SXR. Vitamin K2 with its isoprenoid side chain of varying length will, 
for reasons of simplification, now be referred to as MK‐7, even though there are moieties 
which are both shorter and longer. MK‐7 is chosen, due to the fact that this molecule might be 
the more abundant, as well as the more active moiety.
First, it might be of interest to see which the genes are, and thus, what are the cellular or 
biological functions being ‘determined’ or ‘modulated’ by MK‐7 and its ‘relatives’. A scru-
tiny of the interactions of NR1I2 taken from ‘Gene Cards’: http://string‐db.org/cgi/network.
pl?taskId=I2KNgtQWbVsT looks like this (Figure 1).
It has been well established that NR1I2‐PXR‐SXR is the receptor, which binds vitamin K2 
analogues of different chain lengths, e.g. MK‐4 and MK‐7, and NR1I2 may thus communicate 
the effects of vitamin K2 via associating with RXRA, forming a heterodimer. Furthermore, one 
may postulate that vitamin K2 may influence several other genes indirectly, by ‘impinging’ 
on elements or members of a ‘gene lattice’ like the one shown in Figure 1. Some of the genes 
being putatively strongly affected by vitamin K2 are (text from the same web‐page as referred 
to Figure 1):
RPS6KB1 ribosomal protein S6 kinase, 70 kDa, polypeptide 1; Serine/threonine‐pro-
tein kinase that functions downstream of signalling by mTOR responding to growth 
factors, as well as nutrients in order to sustain cell proliferation, growth and progres-
sion of the cell cycle. It modulates protein synthesis via phosphorylation of EIF4B, RPS6 
and EEF2K, and ensures cell survival via repression of pro‐apoptotic functions of BAD. 
When nutrient depletion occurs, inactive forms associate with EIF3 to build a translation 
initiation complex.
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PPARGC1A peroxisome proliferator‐activated receptor γ, co‐activator 1α; Serves as a tran-
scriptional co‐activator of steroid hormone receptors, as well as nuclear receptors. It greatly 
enhances transcription of the PPARG and thyroid hormone receptors, and can regulate mito-
chondrial genes, contributing to adaptive thermogenesis. It plays a pivotal role in metabolic 
adaptation in response to the availability of various diets via coordinating the expression of a 
large spectrum of genes mandatory for glucose and fatty acid metabolism.
NR1I2 nuclear receptor subfamily 1, group I, member 2; this is the nuclear receptor actually 
binding vitamin K2, and also goes by the names of SXR and PXR.
DYRK2 dual‐specificity tyrosine‐(Y)‐phosphorylation regulated kinase 2; this serine/threo-
nine‐PK is involved in modulatory control of mitosis, proliferation of cellular entities, apopto-
sis, as well as cytoskeleton organization encompassing neurite outgrowth. It functions partly 
via its role in ubiquitin‐dependent degradation of proteasomes. It works downstream of ATM 
to phosphorylate p53/TP53 at position ‘Ser‐46’, thus contributing to induce apoptosis as a 
response to DNA damage. It phosphorylates NFATC1, thus inhibiting its accumulation in the 
nucleus, as well as its activity as a transcription factor.
RBCK1 RanBP‐ and C3HC4‐type zinc finger containing 1; E3 ubiquitin‐protein ligase, accept-
ing ubiquitin delivered by E2 ubiquitin‐conjugating enzymes, one of which is UBE2L3/
Figure 1. Genes interacting with the vitamin K2 (MK‐7 or MK‐4), which bind to the nuclear (transcription factor) NR1I2 
being connected to a network of associated genes. Right panel: high stringency emulation and left panel: intermediate 
stringency.
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UBCM4, thereafter transferred to its substrates. It serves as E3 ligase for oxidized IREB2, 
while heme and oxygen are both necessary for the ubiquitination of IREB2. It promotes 
ubiquitin‐coupling to TAB2 and IRF3, as well as their proteasome‐mediated degradation. 
It is a  component of the LUBAC complex, which conjugates (‘M‐1’‐linked) polyubiquitin 
to substrate molecules, and plays a key role in NF‐ kappa‐B activation and modulation of 
inflammation.
SRC v‐src sarcoma viral oncogene homolog; non‐receptor protein tyrosine kinase being acti-
vated subsequent to engaging of several various classes of cellular receptors, encompassing 
immune response receptors and integrins as well as adhesion receptors, TyrK‐receptor pro-
tein kinases, G protein‐sensitive receptors, and cytokine receptors. It participates in signal-
ling, controlling a plethora of biological phenomena encompassing transcription of genes, 
immune responses, adhesion of cells, progression of the cell cycle, apoptosis, migration as 
well as transformation.
NCOA6 nuclear receptor co‐activator 6; co‐activator of nuclear receptor, directly binding 
nucleoceptors, stimulating transcriptional characteristics in a hormone‐like manner. It co‐
activates expression in an agonist‐ and AF2‐mediated fashion. It is implicated as co‐activa-
tor of various nuclear receptors, like those binding steroids (GR & ERs), retinoids (RARs & 
RXRs), thyroid hormone (TRs), cholecalciferol (D3, VDR), as well as prostanoids (PPARs). It 
probably serves as a ubiquitous co‐activator, instead of just another nucleoceptor co‐activa-
tor. It may furthermore serve as a co‐activator within the NF‐kappa‐B signalling pathway.
RXRA & RXRB retinoid X receptor, alpha & beta; Retinoic acid receptor. These receptors asso-
ciate as heterodimeric entities to target response elements, elicited by their ligands, which are 
all‐trans or 9‐cis retinoic acid, thus regulating the expression of genes responsible for various 
biological processes. The heterodimers of RAR/RXR associate with response elements specific 
for retinoic acids (RAREs) comprising tandem 5’‐AGGTCA‐3’ binding sites, DR1‐DR5 (by 
similarity). They preferentially associate with 9‐cis retinoic acid.
RBBP7 retinoblastoma binding protein 7; nucleocore histone‐associating subunit targeting 
the chromatin‐bound remodelling factors, histone acetyltransferases, as well as and histone 
deacetylases to histone substrates in a way compatible to ‘its’ nucleosomal DNA. It is a con-
stituent of a plethora of complexes, regulating chromatin turnover, which include the type B 
histone acetyltransferase (HAT) complex, required for chromatin assembly subsequent to 
DNA replication; core histone deacetylase (HDAC) complexes, promoting deacetylation of 
histones and consequently transcriptional repression.
SUMO1&2 SMT3 ‘suppressor of mif two 3, homolog 1'; ubiquitin‐like protein which may 
be covalently bound to proteins as a monomeric entity or as a lysine‐linked polymer. It is 
covalently associated via an iso‐peptide bond to its substrates–necessitates prior activation by 
an E1 complex (SAE1‐SAE2) and firm linkage to the E2 enzyme UBE2I. It can be promoted/
facilitated by E3 ligases, such as PIAS1‐4, RANBP2 or CBX4. The present post‐translational 
alteration of lysine‐containing protein residues serves a decisive role in a series of cellular 
processes, such as intra‐nuclear transport, replication and repair of DNA, mitosis, as well as 
signal transduction.
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NCOA2 nuclear receptor co‐activator 2; transcriptional co‐activator for both steroid recep-
tors in general, as well as any type of nuclear receptors. It is the co‐activator of the AF‐2 
steroid binding domain, but not of the AF‐1 modulating N‐terminal domain. It is required 
along with NCOA1 to master the cellular energy balance between white and brown 
adipose tissues.
UBR5 ubiquitin protein ligase E3 component n‐recognin 5; E3 ubiquitin‐protein ligase, 
which serves as one member of the N‐end rule pathway. It recognizes and associates with 
specific N‐terminal protein residues, destabilizing in accordance with the ‘N‐end rule’, lead-
ing to a final ubiquitination with subsequent degradation. It is involved in the maturation 
and/or transcriptional modulation of mRNAs by activating CDK9 (via multiple ubiquiti-
nations). It may serve a role in the progression and control of the cell cycle. It may also 
exert tumor suppressor activity. It modulates the DNA topoisomerase II binding protein 
(TopBP1) activity within in the DNA.
A short and non‐exhaustive summary (for details, see above) of the potential biological impact 
exerted by MK‐7 is quite impressive, and encompasses phenomena like the regulation of: pro-
tein synthesis, the cell cycle, cell survival, cell adhesion, nuclear transport, DNA replication 
and repair, cell phenotype regulation and stabilization via impact on histone deacetylases 
(HDACs), as well as inflammatory processes [1]. As seen from the few genes described above, 
it may be asserted that vitamin K2 is also able to influence bodily phenomena like energy 
(lipid and glucose) metabolism, due to a balance between the amount of bodily distribution 
of white and brown/beige adipocyte phenotypes. It is well known that white adipocytes store 
fat, while brown and beige adipocytes are either directly burning fatty acids only or perform-
ing both tasks simultaneously, in order to balance the characteristics of the other two. A few 
articles describe the versatile biological effects of vitamin K2 analogues in detail, and are 
referred to in the following paragraphs.
The nuclear receptors (NRs), the pregnane X receptor (PXR) and the related constitutive 
androstane receptor (CAR), play important roles as part of the xenobiotic detoxification reac-
tions by modulating the expression of drug‐metabolizing enzymes and transport molecules, 
to aid in the degradation and excretion of foreign chemical substances, as well as endog-
enously produced metabolites. The present survey is seeking to expand on the perceived 
biomedical relevance of both the PXR and CAR beyond their established role as master xeno‐
sensors, rather focusing on disease‐oriented subjects, and with emphasis on their ability to be 
modulated by small molecules. These nuclear receptors are apparently involved in both the 
development and the treatment of non‐alcoholic fatty liver disease (NAFLD). These receptors 
are, in fact, transcription factors (TFs), that are able to sense altering environmental and/or 
hormone‐like signals, thus effectuating transcriptional changes in order to balance vital func-
tions like cell/organ growth, but also development and reproduction. To be able to sustain 
this function, the following ligand‐induced activation by xenobiotics (but also by liganding 
vitamin K2 (e.g. MK‐7), ‘members of subfamily 1 nuclear receptors’ (NR1s) will heterodimer-
ize with retinoid X receptor (RXR) and thus regulate gene transcription modulated processes 
being engaged in energy metabolism, but also inflammation. Many of these receptors, includ-
ing PPARs (peroxisome proliferator‐activated receptors), PXR, CAR, LXR and FXR (pregnane 
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and xenobiotic, constitutive androstane, liver and X) receptors serve as key regulatory ele-
ments of the gut‐liver‐adipose biological axis, but also coordinate metabolic responses within 
organs, when oscillating between the fed and fasting states [2].
Non‐alcoholic fatty liver disease (NAFLD) happens to be the most common liver ailment, 
which may eventually progress to cirrhosis and thereafter develop into hepatocellular 
 carcinoma. NAFLD is characterized by insufficient nuclear receptor activity, leading to dis-
turbed signalling through the gut‐liver‐adipose axis, which encompasses obesity, increased 
‘leakage’ or permeability of the bowel system, with ensuing systemic inflammation, ‘derange-
ments’ of the hepatic lipid metabolism, as well as insulin resistance. Unfortunately, envi-
ronmental chemicals may complicate the issue by directly interfering with these nuclear 
receptors, conferring ‘metabolic confusion’ and thus the inability to distinguish feeding from 
starvation hours. Clinical investigations including conducted in the past (cfr. the PIVENS 
and FLINT trials) have shown that treatments aimed at these nuclear receptors may cause 
paradoxical reactions characterized by a dissociation of phenomena like inflammation, fibro-
sis, insulin resistance, dyslipidemia, steatosis and obesity. However, novel strategies (e.g. 
tissue‐specific ligand molecules and/or dual receptor agonists) may be mandatory to be able 
to separate beneficial effects of nuclear receptor activation from untoward metabolic adverse 
effects [3].
In another investigation, one was looking into the effect of vitamin K2 on aortic calcifica-
tion induced by warfarin via the Gas6/Axl survival pathway. A calcification rat model was 
established where warfarin was given to rats, which were divided into the following groups: 
controls and calcification groups, where some of the animals received vitamin K2. And the 
effect measurements/analyses were as follows: aortic calcium depositions (with Alizarin red); 
alkaline phosphatase activity in serum; apoptosis was evaluated by the TUNEL assay; and 
protein expression levels of Gas6, Axl, phosphorylated Akt (p‐Akt) and Bcl‐2 were analysed 
using western blotting. To summarize the results: the calcium content, calcium depositions, 
ALP activity and apoptosis were significantly higher in the calcification groups than con-
trol group. Furthermore, Gas6, Axl, p‐Akt and Bcl‐2 expression was lower in the calcification 
group than in the control group. Interestingly, 100 μg/g vitamin K2 administration reduced 
calcium depositions, ALP activity, as well as apoptosis, while Gas6, Axl, p‐Akt and Bcl‐2 
expression were enhanced. Furthermore, vitamin K2 reversed almost half of the calcification. 
Finally, there was a positive correlation between formation calcification and apoptosis with 
P < 0.0001. This data therefore provides a sound theoretical basis for future treatments of 
aortic calcification [4].
The impact of vitamin K2 on apoptosis in different types of cancer cells have been shown 
in previous studies. But, the apoptotic effect of K2 on bladder cancer cells has not yet been 
evaluated. Hence, apoptotic activity and the underlying mechanism of K2 in bladder cancer 
cells were investigated. It was shown that K2 induces apoptosis in these cells via the ‘mito-
chondria pathway’ (i.e. membrane potential, cytochrome C release and the caspase‐3 cas-
cade). Also, phosphorylation of c‐Jun N‐terminal kinase (JNK) and p38 MAPK was detected 
in the vitamin K2‐treated cells. Generation of ROS (reactive O2 species) was observed in the cancer cells, however, treatment with K2 and the anti‐oxidant N‐acetyl cysteine  virtually 
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blocked the K2‐triggered apoptosis, loss of mitochondrial membrane potential, as well as the 
JNK and p38 MAPK phosphorylation. These findings show that vitamin K2 clearly induces 
apoptosis in bladder cancer cells via the ROS‐mediated JNK/p38 MAPK and mitochondrial 
 pathways [5].
The pregnane X receptor (PXR) was until recently considered to serve as a nuclear recep-
tor deemed to be specialized for detecting exposure from xenobiotics. In concurrence with 
this characteristic, PXR was identified to modulate drug‐metabolizing enzymes. During the 
 previous decades, PXR shown to harbour a broader spectrum of features. It is now evident that 
ligand‐activated PXR modulates hepatic glucose turnover and lipid metabolism, while also 
affecting metabolic homeostasis throughout the whole body. At present, the consequences of 
PXR‐elicited modulation on overall metabolic health, are not fully investigated, however, it 
has been shown that Rifampicin as well as St. John’s wort, both serving as prototypical human 
PXR agonists, impair glucose tolerance in healthy individuals. Therefore, chronic exposure 
to naturally occurring PXR‐agonists could be construed as a risk factor for diabetes and the 
metabolic syndrome [6].
As one associate of heterodimeric couples (ligand‐receptor complexes), the retinoid X recep-
tor (RXR) plays a leading role within the superfamily of nuclear receptors (NRs). Some 
heterodimers, e.g. PPAR&RXR, LXR&RXR, as well as and FXR&RXR are perceived as ‘per-
missive’, i.e. they turn into active transcriptional moieties, when an RXR‐selective ligand 
(‘rexinoid’) or an NR partner ligand is present. In contrast, the so‐called ‘non‐permissive’ 
heterodimers (such as RAR&RXR, VDR&RXR or TR&RXR) are non‐responding (inert) to 
the ‘rexinoids’ in question, when alone. Nonetheless, the agonists turn into ‘transcriptional 
activators’, when appearing together with a synergizing partner. However, despite their con-
stellations assumed, when serving within the heterodimer formation/activation of multiple 
pathways, RXR appears as a target for drug discoveries. Interestingly, a rexinoid is applied 
in the clinic for the treatment of cutaneous T‐cell lymphoma. More importantly, a plethora of 
RXR modulators also beholds a therapeutical ability for the treatment of metabolic diseases. 
The modulatory ‘skill’ of the rexinoids lies in the ligand‐receptor complex conformation, 
as well as the wide spectrum and extent of their association with co‐regulators, thus sus-
taining the specificity of the physiological response elicited. Interestingly, collected genetic 
and pharmacological data, emanating from investigations of insulin sensitivity, diabetes and 
obesity, definitely conclude that RXR agonists and antagonists show great promise as anti‐
obesity agents [7].
Unfortunately, the ‘therapy’ with rexinoids enhances plasma triglycerides, suppresses the 
hypothalamic‐pituitary‐thyroid hormone axis, as well as induces hepatomegaly, which 
complicates further search for compounds to treat insulin resistance and type 2 diabetes 
mellitus (T2DM). The recently developed PPARγ/RXR and LXR/RXR heterodimer‐selective 
rexinoids, acting differently from PPARγ or LXR agonists alone, could possibly circumvent 
these limitations. Suffice to say, therapy with vitamin K2 alone (either as MK‐7 or MK‐4) in 
combination with a suitable rexinoid, might overcome the treatment ‘paradox’ described 
above [7].
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The steroid and xenobiotic receptor (SXR) and its murine orthologue, the pregnane X recep-
tor (PXR), are, as mentioned many times over, expressed in the liver and intestine where, 
they function as xenobiotic sensors involved in detoxification and drug excretion. However, 
it has recently been shown that both SXR and PXR are present in osseous tissue, where 
they facilitate bone metabolism [8]. It was shown that a deletion of PXR provokes in an 
ageing‐dependent wearing of the articular cartilage in knee joints. A histomorphometrical 
analysis demonstrated a marked diminution of the width of, as well as an enlarged gap 
between, articular cartilage of the femur and tibia in PXR‐knockout mice. It was therefore 
speculated that the up‐regulated SXR in the chondrocytes play a protective role in articular 
cartilage. Interestingly, the Fam20a (family‐with‐sequence‐similarity‐20a) gene proved to 
be an SXR‐sensitive gene, known to be induced by SXR ligands, such as rifampicin and 
vitamin K2 (MK‐7) [8].
Furthermore, it was proven that the expression of Fam20a was primarily seen in articular 
chondrocytes. Consistent with the epidemiological data given, the present results strengthen 
the notion that SXR/PXR may protect against ageing‐dependent detrimental wearing of artic-
ular cartilage, and, therefore, one may assert that ligands for SXR/PXR (such as vitamin K2) 
may prevent the induction of osteoarthritis due to ‘old age’ [9].
The fat‐soluble vitamin K1 is involved in blood coagulation mediated by maintaining the 
activity of coagulation factors in the liver. However, the vitamin K2 variety exerts extrahe-
patic ‘abilities’ known to prevent bone fractures. In addition, epidemiological studies suggest 
that a lack of vitamin K (mainly K2) is associated with several geriatric diseases, including 
osteoporosis (bone brittleness), osteoarthritis (inflamed joints), dementia (mental retardation) 
and arteriosclerosis (blood vessel stiffness/narrowing). Furthermore, it was demonstrated 
that vitamin K may serve as an important factor in the prevention and/or treatment various 
types of cancers [10].
Recently, a novel role was discovered for vitamin K, serving as a ligand of the nuclear,  steroid 
and xenobiotic receptor (SXR), as well as its murine, pregnane X receptor (PXR) orthologue. As 
a supplement to its published function as a co‐factor for the γ‐glutamyl carboxylase (GGCX), 
which effectuates a plethora of post‐transcriptional changes, vitamin K also displays an addi-
tional mode of action, which is conveyed via transcriptionally modulations of the SXR/PXR 
target genes. Investigations of bone chips from PXR‐deficient animals (mice) demonstrated 
that the osseous protection impact of vitamin K is partially conveyed via SXR/PXR‐dependent 
signals. The discovery of new ways, by which vitamin K acts, has unravelled novel hope that 
this little molecule might come in handy in the prevention and/or treatment of a series of dis-
eases affecting the elderly [10].
The steroid and xenobiotic/pregnane X receptor (SXR/PXR) is a nuclear receptor, which is 
located mainly in hepar and intestine, where they serve as xenobiotic sensors. However, 
many groups have identified SXR/PXR as a ubiquitous mediator of bone homeostasis. It was 
shown that systemic deletion of PXR brings about a marked loss of bone tissue (osteopenia) 
characterized by mechanical fragility in experimental animals (mice) down to 4 months of 
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age. Values for BMD (bone mineral density) of PXR knockout (PXRKO) animals decreased 
substantially, when compared with BMD‐values of wild‐type animals. Micro‐computed 
tomography measurements of trabecular bone (femur) from PXRCO animals unravelled a 
3D‐bone volume fraction markedly lower than what was found for WT mice [9].
Furthermore, histomorphometrical measurements of the trabecular bone material from 
the proximal tibia demonstrates a marked diminution bone mass from the PXRKO mice. 
Furthermore, bone formation was reduced, whereas bone resorption was augmented in the 
PXRKO mice. Histomorphometrical measurements of femoral cortical bones unravelled 
larger cortical areas in control animals than in PXRKO animals. The WT mice displayed an 
augmented cortical width, compared with PXRKO controls, and the so‐called ‘three‐point 
bending test’ showed that the ‘new’ morphological phenotypes in fact led to significant 
mechanical fragility. And, not to forget, serum levels of phosphate, as well as calcium and 
alkaline phosphatase remained unaltered in the PXRKO mice, as compared with their WT 
littermates. Consequently, it was concluded that SXR/PXR‐activation augments the bone for-
mation/resorption ratio, thus carving out a role for SXR/PXR as the key ‘provider’ of bone 
health [9].
The steroid and xenobiotic receptor (SXR = PXR = NR1I2) is activated by a plethora of endoge-
nous hormones, pharmaceutics (drugs), as well as xenobiotics. SXR exhibits an enlarged, flex-
ible and hydrophobic domain (LBD) for the ligand binding, and this is markedly divergent 
across different species of mammals. SXR also displays a pronounced difference in its phar-
maco‐dynamics and ‐kinetics amongst different mammalian species. The versatile response 
profile of SXR has paved the way for launching a ‘steroid and xenobiotic binding hypothesis’. 
SXR is well‐established as a xenobiotic sensor, which in a coordinated fashion rules the clear-
ance of xenobiotics from the liver and intestine, through the up‐regulation of genes being 
instrumental in both drug and xenobiotic turnover and excretion. Recently, it was revealed 
that SXR (most unexpectedly so) in fact makes a major contribution to (1) subduing inflam-
mation, (2) bone homeostasis, (3) vitamin D turnover, (4) lipid metabolism, (5) energy homeo-
stasis, as well as (6) the body's defence against cancer. Hence, the discovery of SXR as more 
than a xenobiotic sensor enables the use of a powerful tool for scrutinizing new mechanisms 
via which dietary factors, chemicals and the environment ultimately impact health, as well as 
disease development, prevention and treatment [10–13].
It has since long been shown that the xenobiotic receptors (XRs) have functionally evolved 
into cellular sensors for both endogenous and exogenous stimuli. Over the past decade, it has 
been demonstrated that regulating of the transcription of genes encoding drug‐metabolizing 
enzymes and transporters, as well as the genes involving energy homeostasis, cell prolifera-
tion and/or immune responses are sensitive to the XRs. Unlike prototypical steroid hormone 
receptors, XRs are activated through both direct ligand‐binding and ligand‐independent 
(indirect) mechanisms by a plethora of structurally unrelated chemicals. In particular, scru-
tiny has been on the signalling control of the constitutive androstane receptor (CAR), the 
pregnane X receptor (PXR), as well as the aryl hydrocarbon receptor (AhR), which, in this 
context, function together in a synergistic manner. The latter (AhR) normally activates natural 
killer (NK) cells residing within the liver [10–13].
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Ever since the identification of the retinoid X receptor (RXR) being a member of the nuclear 
receptor (NR) superfamily, the interest it has created has unravelled new understanding of 
its physiological regulation by nuclear receptors. Biologically, RXR serves an important role 
via its potent ability to associate with a variety of nuclear receptors. RXR possesses the abil-
ity to modulate nutrient metabolism via forming so‐called ‘permissive’ heterodimers with 
PPAR (peroxisome proliferator‐activated receptor), the liver‐X‐receptor (LXR), the farnesoid 
X receptor (FXR), the pregnane X receptor (PXR) and the constitutive androstane receptor 
(CAR), of which all of them start being functional, when ligands are associated to one or both 
of these heterodimers [10–13].
On the other hand, RXR will form ‘non‐permissive’ heterodimers with the VDR (vitamin 
D receptor), TR (thyroid receptor), as well as RAR (retinoic acid receptor), which function 
 properly only when vitamin D, T3 and retinoic acid, respectively, are present. Furthermore, 
RXR can form homodimers in the presence of a selective agonist, rexinoid, to regulate gene 
expression and to either inhibit proliferation or induce apoptosis in human cancers. Thus, 
over the last 25 years there have been several reports on the design and synthesis of small 
molecule RXR selective agonists, rexinoids [10–13].
A summary of some of the end point effects of agonists of the make: PXR/LXR (Figure 2, left 
panel), which appear to be working through the PI3K‐AKT signalling pathway (Figure 2, 
right panel).
On the left‐hand figure, the pathways of T4 (via the deiodinase DIO3) and T3 are indi-
cated. The keen reader will definitely study the chart for her‐ or himself, however, suffice 
to emphasize that there are the biological pathways or cellular functions on which recep-
tors PXR/RXR and LXR/RXR exert powerful biological impacts: metabolism in general, cell 
Figure 2. Summaries of genes impinging on metabolic pathways in general, cell proliferation, lipid (including 
cholesterol) metabolism with emphasis on the impact of DIO3 (deiodinase 3), and ‘KEGGs Pathways’ showing 
how the PI3K‐AKT regulatory system affects a plethora of metabolic functions. Source: http://www.biochemj.org/
content/453/1/71; http://www.genome.jp/kegg‐bin/show_pathway?hsa04151.
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proliferation, lipogenesis, lipolysis, cholesterol metabolism, carbohydrate metabolism, 
steroid metabolism, feedback inhibition of T3 and T4, muscle contraction, coagulation, 
thermogenesis, cell communication, sperm function, exocytosis, cell cycle regulation, and 
CNS function [14]. On the right‐hand figure, the reader can observe that the PI3K‐AKT 
signalling pathway, used by both osteoblasts or fibroblasts/HUVEC/VIC cell phenotypes 
to ensure or block the development of mineralizing properties [1], or described as mod-
ulators of GSK3, Bcl‐2, RXRα and NFκB, and the FOXO‐family of transcription factors, 
which are involved in biological phenomena summarized as glycolysis/gluconeogenesis, 
cell cycle, apoptosis, and NFκB/p53‐ signalling, of which all of them can and should be 
construed as adaptors of cell ‘lifetime’ = survival and ‘phenotype’ = functional stabiliza-
tion [14].
As can be seen from Figure 2, it should be quite clear (or rather obvious?) that vitamin K2 
(e.g. MK‐4 or MK‐7) exerts a spectrum of effects on various organs, and not only serves as a 
 vitamin/hormone with an impact on coagulation mineralization of bone and demineraliza-
tion of soft tissues like blood vessel walls (ref). And there are numerous reports to be found 
asserting a much broader function of vitamin K2, here are but a few:
(1) ‘The steroid and Xenobiotic receptor (SXR), beyond xenobiotic metabolism’ [15], which 
describes the impact of vitamin K2 on cholesterol and lipid homeostasis, bile acid homeo-
stasis, inflammatory bowel disease (featuring SXR and NFκB), interplay between SXR 
and other receptors like CAR, FXR, VDR, the implication of SXR in cancer develop-
ment and treatment, the implication (synergy) of SXR, and FoxO1, and FoxA2 in energy 
homeostasis.
(2) ‘Role of Pregnane X Receptor in Obesity and Glukose Homeostasis in Male mice’ [16], 
where PXR (the receptor binding vitamin K2) knock‐out mice display weight increase, 
with a concomitant increase in liver weight (hepatomegalia), hyperinsulinemia and 
hypoadiponectinemia, as well as a loss of R2 receptors for adiponectin. These trends are 
all associated with the development of type II diabetes (T2DM).
(3) ‘Targeting xenobiotic receptors PXR and CAR for metabolic diseases’ [17], where the 
pregnane X receptor (PXR) and the constitutive androstane receptor (CAR) was found 
to be involved in normalizing metabolic disorders like the metabolic syndrome, T2DM, 
dyslipidemia, as well as atherosclerosis.
(4) ‘Novel Functions of PXR in cardiometabolic disease’ [18], where the authors in the 
abstract asserts that recent studies have revealed novel and unexpected roles of PXR in 
modulating obesity, insulin sensitivity, lipid homeostasis, atherogenesis, and vascular 
functions. These studies suggest that PXR signalling may contribute significantly to the 
pathophysiological effects of many known xenobiotics on cardiometabolic disease in 
humans. Genes mentioned in this article are many, and classified under functions like: 
‘cholesterol and lipid metabolism’, ‘lipoprotein metabolism’, glucose metabolism’, cho-
lesterol and lipid metabolism’, ‘inflammation and atherosclerosis’, detoxification and 
oxidative stress protection’.
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(5) ‘Regulation of PXR and CAR by protein‐protein interaction and signalling crosstalk’ 
[19], where the authors assert that ‘it is clear that PXR and CAR perform a much 
broader range of cellular functions through protein‐protein interactions and signal-
ling crosstalk, which typically mutually affect function of all the partners involved. 
Future research on PXR and CAR should, therefore, look beyond their xenobiotic 
functions’.
(6) ‘Mechanism of xenobiotic receptor activation: Direct vs indirect’ [20], where the authors 
focus on the nuclear receptor (NR; remember that SXR = PXR also goes by the name 
NR1/2 = Nuclear Receptor 1/2) and its mode of activation, via pairing with a different 
nuclear receptor partner (activators/inhibitors, such as RXR, CCRP, NCOR, SMRT and 
several others). PXR may also be activated indirectly, which contributes to a meticulous 
and intricate regulatory system. Suffice to say that vitamin K2 (e.g. MK‐7 or MK‐4) is, but 
one factor contributing to the activation of NR1I2 = SXR = PXR, and is probably depen-
dent on a certain intra‐cellular/intra‐nuclear level (as a ‘cut‐point’ for proper activation) 
to exert a significant/maximal effect.
These six reports (of several more) signify that vitamin K2 may and will be of significance as 
to optimize and/or maximize certain toward effects, beneficial to organ systems in the body, 
as well as optimization of inter‐organ cross‐talk for the benefit of organ health and homeosta-
sis. Finally, it should be mentioned that microRNAs play an important part in the regulatory 
network determining the impact of nuclear proteins responsible for proper gene expression—
metabolic function—cell phenotype ‘development’ and stabilization.
1. Role of microRNAs in the determination of cellular phenotype
MicroRNAs (miRNAs or miRs) are conserved, small non‐coding RNAs (18–25 nucleotides 
long) instrumental in the regulation of gene expression, and serve as a part of a network 
of factors, including transcription factors determining the phenotype of a certain cell in the 
body (ref). The transcription factors, such as the SXR = PXR = NR1I2 serve as receptors, much 
the same way as the receptors for vitamin A (RXR) and D (VDR), and may modulate gene 
transcription to determine the cell phenotype with its defined phenotypic characteristics (e.g. 
mineralizing osteoblast or non‐mineralizing vessel‐lining epithelial cells or heart valve fibro-
blast). It is well known that vitamin K2 (MK‐7) stabilizes the two phenotypes (also in the 
presence of an inflammatory environment), thus preserving ‘correct’ inter‐organ cross‐talk, 
as would be expected in a healthy organism.
First, it should be emphasized that vitamin K2 binds to a nuclear receptor, which is part of 
a regulatory network consisting of microRNAs and other transcription factors. Second, this 
network represents a minimal lattice of regulatory factors, which may be manipulated in order 
to breach the stability of a certain cell phenotype (e.g. a cancer cell), or doing the opposite: 
reinforcing the phenotype in question (e.g. mineralizing osteoblast and non‐mineralizing fibro-
blast during renal failure, uremia, for instance). Without going into detail, it is asserted that the 
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regulatory networks presented here bargain for: (1) how vitamin K2 is involved in the stabiliza-
tion of the osteoblastic phenotype, and (2) which are the major players (microRNAs and genes) 
determining whether a cell will adapt mineralizing properties or not (osteoblast or fibroblast).
Suffice to say (with reference to Figure 3), the master transcription factor JUN, impinges on 
a set of microRNAs (let‐7 species) in a hierarchical structure of traditional genes and other 
microRNAs, which are well known in the literature, as being part of the WNT‐Notch, the 
TGFβ and the BMP pathways (determining the osteoblast phenotype) (see KEGGs pathways), 
where specific markers like WNT6, DKK1, and CTNNB1 (β‐catenin, activator of Runx2, the 
most referred marker of osteoblastic cells), are represented, and where some of the major 
microRNA‐species, like miR‐125, miR‐21, miR‐221, miR‐27 and miR‐23, known to be impor-
tant in the differentiation and stabilization of the osteoblast phenotype is ensured.
In very much the same way, one may analyse the gene‐transcription factor—microRNA axis 
in conditions like non‐alcoholic fatty liver disease (NAFLD) or non‐alcoholic steatohepati-
tis (NASH), and hopefully arrive at blood‐born microRNAs, representing the diseases in 
Figure 3. The involvement of vitamin K2 (MK‐4 and MK‐7), binding to NR1I2 = SXR = PXR, exerting its effect via hsa‐
miri‐760 on regulatory loops in osteoblasts (according to the Mir@nt@n algorithm). This chart shows how vitamin K2 
may affect the regulatory system determining the phenotype of osteoblast as a mineralizing cell in the body, involving 
microRNAs, transcription factors (e.g. FOS, JUN, SP1 & SP3) and ‘functional’ or ‘marker’ genes, like RUNX1.
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 question and/or their severity. MicroRNA species and putative target genes related to liver 
disease (NAFLD & NASH), as well as cardio (vascular) affection were pooled from three dif-
ferent articles (Figure 5).
At highest stringency applied, there are but a few genes and microRNAs emerging as ‘con-
nected’: hsa‐mir‐122 with FBXO32 (F‐Box protein 32; involved in FOXO‐mediated signal-
ling) and STAT4 (transcription factor); hsa‐mir‐144 with ABCA1 (ATP binding cassette 
subfamily A member 1, involved in cholesterol and sphingolipids transport from golgi and 
ER to the apical membrane and regulation of lipid metabolism by PPARα), hsa‐mir‐33b 
with ABCA1 and SLC25A25 (solute carrier family 25 member 25), and finally hsa‐mir‐145 
with TFAM (transcription factor A, mitochondrial). Without going into details, all three 
articles [21–23], emphasize microRNA species 122, 144, and 33b, as instrumental in regu-
lating hepatic lipid metabolism, with emphasis on hsa‐mir‐122. This microRNA‐species is 
instrumental in the optimization of fatty acid oxidation vs synthesis, cholesterol produc-
tion, as well as VLDL secretion to the circulation, and thus determining the health status 
of any individual in terms of risk of incurring atherosclerosis. The fact that this regulatory 
system, shown in Figure 4, lacks reciprocal regulatory loops makes it more vulnerable and 
Figure 4. Hierarchical regulatory system consisting of microRNAs, transcription factors and genes involved in the 
mineralization phenotype of osteoblastic cells, but also present in fibroblasts having attained untoward/unwanted 
mineralizing properties during exposure to inflammatory cytokines and/or co‐cultured with Th‐1 and Th‐17 cells.
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unstable, when threatened by ‘disease states’, like NAFLD/NASH, than systems found in 
the osteoblast, which apparently appears more resilient to change, when exposed to condi-
tions where inflammation prevails.
Finally, it should be emphasized that bioinformatics analyses of the ‘NRI2‐relative’ NR1I3, 
the constitutive androstane receptor (CAR), which interacts with NR1I2 = SXR = PXR, is also 
biologically interfering with many of the same factors (e.g. PPARα, CEPBα, STATs and T3) 
[24], thus linking them together in a very tight regulatory network, affecting lipid metabolism. 
Understanding the impact of vitamin K2 on these regulatory systems seems to be mandatory to 
grasp and acknowledge the idea that this fat‐soluble molecule exerts such a tremendous effect 
on biological processes compatible with organ health, disease free old age, and thus ‘longevity’.
Figure 5. MicroRNAs, transcription factors and ‘functional’ genes related to liver function in patients with NAFLD/
NASH with or without metabolic cardiovascular disease (see Refs. [21–23]). The three charts represent decreasing 
stringency/from top to bottom), and it should be emphasized that the regulatory system does not contain any 
reciprocal regulatory feedback systems, as was shown for the ‘stabilization’ of the osteoblast (or mineralizing 
phenotype).
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Addendum 1
List of microRNAs and genes used as ‘input’ into the Mir@nt@n‐algorithm, asking the pro‐
gram to ‘retrieve’ regulatory networks
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